[The thromboembolic risk of atrial fibrillation]

Area of Science:

• Cardiology
• Vascular Medicine
• Pharmacology

Background:

• Thrombo-embolic risk assessment in atrial fibrillation is well-established.
• Clinical and echocardiographic criteria help identify predictive factors for thrombo-embolism.
• Stratifying patient risk guides appropriate therapeutic strategies for thrombo-embolic and hemorrhagic profiles.

Purpose of the Study:

• To review the current understanding of thrombo-embolic risk assessment in atrial fibrillation.
• To evaluate the efficacy of oral anticoagulation compared to aspirin.
• To define therapeutic approaches for recent-onset atrial fibrillation.

Main Methods:

• Review of recent clinical trials on oral anticoagulation in atrial fibrillation.
• Analysis of predictive factors for thrombo-embolism (clinical and echocardiographic criteria).
• Evaluation of therapeutic strategies based on risk stratification and timing of cardioversion.

Main Results:

• Oral anticoagulation with coumarinics (INR 2-3) provides greater protection than aspirin for high-risk atrial fibrillation patients.
• Hemorrhagic complication rates with coumarinics are acceptably low.
• For recent-onset atrial fibrillation, cardioversion without prolonged anticoagulation is feasible within 48 hours of arrhythmia onset.

Conclusions:

• Oral anticoagulation is a key strategy for managing atrial fibrillation thrombo-embolic risk.
• Risk stratification allows for personalized treatment plans balancing efficacy and safety.
• Timely intervention, including cardioversion within 48 hours, is crucial for recent-onset atrial fibrillation.